Cancer Family
Respiratory System Neoplasm
CI-CAN-00000049Explore in graph →
Non-malignant2,727 active trials51 approved drugs619 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000049Explore in graph →
Clinical trials
11,611 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05801107 | Study to Investigate the Efficacy and Safety of WX-0593 in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients | unknown | Phase 2 | 30 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 6, 2023 | clinicaltrials |
| NCT05802641 | Stereotactic Radiotherapy With Different Fractionation Modes for the Early Lung Cancer(DSBRT-1) | unknown | — | 100 | Peking University Third HospitalOTHER | 1 | Apr 6, 2023 |
| clinicaltrials |
| NCT04840004 | Efficacy and Safety of PVT-1 Treatment in Patients With Advanced Non-Small Cell Lung Cancer | unknown | Phase 2 | 24 | PlusVitech S.L.OTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT05799027 | Raman Spectroscopic Analysis of Bronchoscopic Biopsy for Diagnosing Lung Cancer | unknown | N/A | 200 | China-Japan Friendship HospitalOTHER | 0 | Apr 5, 2023 | clinicaltrials |
| NCT04821570 | To Assess Immunogenicity of Coronavirus Disease 2019 (COVID-19) Vaccine in Cancer Patients Receiving Cancer Treatment(CANINE) | unknown | — | 500 | University of Kansas Medical CenterOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT03991403 | Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC | unknown | Phase 3 | 228 | Samsung Medical CenterOTHER | 1 | Apr 3, 2023 | clinicaltrials |
| NCT05769504 | Examining Clinical Trial Participation for Small Cell Lung Cancer Patients | unknown | — | 500 | Power Life Sciences Inc.INDUSTRY | 0 | Apr 3, 2023 | clinicaltrials |
| NCT05794529 | Lung Tumor Protein Synthesis Rates in Lung Cancer Patients(LungMaas) | unknown | — | 30 | Maastricht University Medical CenterOTHER | 1 | Apr 3, 2023 | clinicaltrials |
| NCT04646837 | Mechanism of Response to IMFINZI Neoadjuvant Therapy in Non-small Cell Lung Cancer Patients Based on Multiple-omics Models | unknown | Phase 1 / Phase 2 | 20 | Peking Union Medical College HospitalOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT04974879 | Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer | unknown | Phase 2 | 20 | Qingdao Central HospitalOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT05104281 | Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer | unknown | Phase 3 | 60 | Qingdao Central HospitalOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT05156515 | PD-L1 Targeting Nanobody Probe for PET Imaging of Solid Tumor | unknown | N/A | 20 | Peking University Cancer Hospital & InstituteOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT05789498 | Investigating the Biomarkers in Tumor and Peripheral Blood to Evaluate the Efficacy of Cancer Immunotherapy in Chest Cancer Patients | unknown | — | 60 | Zhao JunOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT02504346 | AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational Studies(TREM) | unknown | Phase 2 | 200 | Oslo University HospitalOTHER | 5 | Mar 28, 2023 | clinicaltrials |
| NCT03066271 | Pre Radiotherapy Daily Exercise Training in Non-Small Cell Lung Cancer(PRIME) | unknown | N/A | 40 | Rigshospitalet, DenmarkOTHER | 1 | Mar 28, 2023 | clinicaltrials |
| NCT05555212 | To Evaluate the Efficacy of QLH11811 in Advanced NSCLC Patients With EGFR Mutation | unknown | Phase 1 | 72 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 28, 2023 | clinicaltrials |
| NCT05785208 | Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status.(TEMPLE-2) | unknown | Phase 4 | 122 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 27, 2023 | clinicaltrials |
| NCT00526396 | STAD-1 Small Cell Lung Cancer Toxicity Adjusted Dosing Study(STAD-1) | unknown | Phase 3 | 160 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT01405586 | MILES-3: Cisplatin in Combination With Gemcitabine for Elderly Patients With Lung Cancer(MILES-3) | unknown | Phase 3 | 299 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT01656551 | MILES-4: Study Comparing Gemcitabine and Pemetrexed, With or Without Cisplatin, in Patients With Nonsquamous Lung Cancer(MILES-4) | unknown | Phase 3 | 232 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT02035683 | PET/CT Scan as a Tool to Rationalize the Treatment of of Advanced NSCLC Patients Undergoing First Chemotherapy(PETRA) | unknown | N/A | 220 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT02633189 | Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer(BEVERLY) | unknown | Phase 3 | 200 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT03975114 | A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5)(MILES-5) | unknown | Phase 2 | 460 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT05782764 | A Study of Endostar Combined With Chemotherapy and Immunotherapy in Lung Squamous Cell Carcinom | unknown | Phase 4 | 30 | Xuzhou Medical UniversityOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT03833193 | Moderate Hypofractionated Radiotherapy for Lung Cancer | unknown | N/A | 60 | North China Petroleum Bureau General HospitalOTHER | 1 | Mar 23, 2023 | clinicaltrials |
| NCT04396457 | Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901 | unknown | Phase 2 | 50 | National Hospital Organization Nagoya Medical CenterOTHER | 1 | Mar 23, 2023 | clinicaltrials |
| NCT04992715 | PD-L1 Expression in Lung Cancer(PELICAN) | unknown | Phase 2 | 15 | NanoMab Technology (UK) LimitedINDUSTRY | 1 | Mar 22, 2023 | clinicaltrials |
| NCT05778045 | Examination of Trends in Non-Small Cell Lung Cancer Patients' Medical Study Experiences | unknown | — | 500 | Power Life Sciences Inc.INDUSTRY | 0 | Mar 21, 2023 | clinicaltrials |
| NCT04519983 | Efficacy of SRT as Salvage Therapy in Patients With Brain Oligo-progression of EGFR-mutant Non-small Cell Lung Cancer After Failure of the Third-generation EGFR-TKIs | unknown | Phase 2 | 40 | Shanghai Cancer Hospital, ChinaOTHER | 1 | Mar 20, 2023 | clinicaltrials |
| NCT05620199 | Upfront Resection of Locally Advanced NSCLC Followed by Chemoradiotherapy(UPLAN-I) | unknown | N/A | 20 | The Netherlands Cancer InstituteOTHER | 0 | Mar 20, 2023 | clinicaltrials |
| NCT04391283 | First Line Osimertinib for EGFR Mutation-positive Non-Small Cell Lung Cancer in Real World Chinese Setting | unknown | — | 500 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Mar 17, 2023 | clinicaltrials |
| NCT02931942 | Changing Over Time of Ascorbic Acid After Chemotherapy | unknown | — | 150 | Maastricht University Medical CenterOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT05771207 | Effects of Protein on Muscle, Gut Microbiota and Clinical Outcome in Patients With Lung Cancer-related Sarcopenia | unknown | N/A | 90 | Peking Union Medical College HospitalOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT05770063 | Effect of Compound Amino Acid Tablets on Nutritional Status of Patients With Lung Cancer | unknown | N/A | 86 | Beijing Chest HospitalOTHER | 0 | Mar 15, 2023 | clinicaltrials |
| NCT04703153 | LIQUIK: LIQUId Biopsy for Detection of Actionable Genomic BiomarKers in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)(LIQUIK) | unknown | — | 151 | Lucence Health Inc.INDUSTRY | 1 | Mar 9, 2023 | clinicaltrials |
| NCT05761977 | Durvalumab in Combination With Standard Chemotherapy of Patients With Extensive Stage Small Cell Lung Cancer(DRIVE) | unknown | — | 50 | Hellenic Cooperative Oncology GroupOTHER | 1 | Mar 9, 2023 | clinicaltrials |
| NCT05127382 | Osimertinib as 1st Line Therapy for Patients With Advanced EGFR Positive Non-Small Cell Lung Cancer | unknown | — | 40 | Hellenic Cooperative Oncology GroupOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT05429866 | Immunological Variables Associated to ICI Toxicity in Cancer Patients | unknown | Phase 2 | 441 | Jules Bordet InstituteOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT04338620 | Camrelizumab Combined With Albumin-bound Paclitaxel and Platinum in Neoadjuvant Treatment of Resectable NSCLC | unknown | Phase 2 | 94 | Tang-Du HospitalOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT05754736 | Clinical Study of Ametinib Combined With Bevacizumab in First-line Treatment of Advanced NSCLC With EGFR-mutations. | unknown | Phase 2 | 50 | The Second Affiliated Hospital of Shandong First Medical UniversityOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT03475953 | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors(REGOMUNE) | unknown | Phase 1 / Phase 2 | 747 | Institut BergoniéOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT05746598 | Effect of Genetic and Epigenetic Factors on the Clinical Response and Toxicity to Cisplatin Among Egyptian Non-small Cell Lung Cancer Patients | unknown | — | 178 | Ain Shams UniversityOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT05741021 | A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 2 | 84 | Shandong New Time Pharmaceutical Co., LTDINDUSTRY | 1 | Feb 24, 2023 | clinicaltrials |
| NCT05738317 | Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel in Non-squamous NSCLC After First-line Treatment | unknown | Phase 2 | 45 | Xiaorong DongOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT04811001 | Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations(CAPLAND) | unknown | Phase 2 | 170 | Fondazione Ricerca TraslazionaleOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05111197 | Local Ablative Stereotactic Radiotherapy for Residual Hypermetabolic Lesion in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Long-term Responders to Immunotherapy(TRAILOCLORI01) | unknown | Phase 3 | 112 | Institut Cancerologie de l'OuestOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05736991 | Deep Learning Signature for Predicting the Novel Grading System of Clinical Stage I Lung Adenocarcinoma | unknown | — | 600 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05737589 | Circulating Tumor DNA and T Cell Repertoire Predict Radiotherapeutic Outcomes in NSCLC Patients With Brain Metastasis | unknown | — | 50 | Xiaorong DongOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT03085069 | A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC | unknown | Phase 2 | 146 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 16, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Apr 6, 2023source: clinicaltrials